Figure 1From: The cost-effectiveness of growth hormone replacement therapy (Genotropin®) in hypopituitary adults in SwedenMarkov structure for cost-effectiveness model. Possible transitions are indicated by arrows. Diseases considered: CHD, coronary heart disease.Back to article page